FIELD: biotechnology.
SUBSTANCE: invention relates to bispecific antibodies to human beta-amyloid and human transferrin receptor, and can be used in medicine.
EFFECT: obtained antibodies consisting of two pairs of light and two pairs of heavy chain antibody and heavy chain-conjugated Fab fragment with SEQ ID NO: 6–9, SEQ ID NO: 1–3, 10, SEQ ID NO: 11–13 or SEQ ID NO: 14–17, can be used for binding beta-amyloid and transferrin receptor.
7 cl, 10 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES TO HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR AND METHODS FOR THEIR USE | 2016 |
|
RU2753390C1 |
| HUMAN TLR7 ANTIBODY | 2019 |
|
RU2808123C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
